ETFs Holding MDVN »    MDVN Historical Stock Prices »
MDVN News Video: Mon, Aug 29, 2016, 12:23 PM — Monday's ETF with Unusual Volume: PBE

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Medivation is a biopharmaceutical company focused on the development and commercialization of therapies to treat diseases. Co. has one commercial product, XTANDI® (enzalutamide) capsules (XTANDI), through its collaboration with Astellas Pharma, Inc. XTANDI has marketing approval in the U.S., Europe and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer, and in Japan for the treatment of patients with castration-resistant prostate cancer. Co. also has worldwide rights to talazoparib (MDV3800), an orally available poly-ADP ribose polymerase inhibitor, and pidilizumab (MDV9300), an antibody with immune-mediated anti-tumor effects. Self directed investors in Medivation Inc will be interested in keeping up with all Medivation Inc news they can find, both MDVN news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on MDVN. At RediNews, we simplify this task by presenting both MDVN news releases originating from Medivation Inc itself, and MDVN news from a variety of media outlets. Visitors can browse this news online and through our MDVN RSS news feed.


MDVN News — Articles, Videos, & Press Releases

MDVN is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:

HMA News
MCK News
CHE News

Consider RediNews RSS feeds to complement your web page financial content. Whether below a detailed quote page, a stock history chart, or featured on your home page, RediNews has an RSS feed to meet your needs. Integrate news by specific stock symbol, or an entire market sector. Simply navigate to any RediNews news page by specific ticker symbol, then click the RSS icon for any news page to reach the associated RSS feed (the icon will look like this): .

MDVN News | | Copyright © 2013 - 2019, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.